基于无创检测动态的MASLD个体化肝相关事件风险预测
研究基于国际多中心VCTE-Prognosis队列,纳入13627例MASLD患者,利用关节潜在类别模型整合无创肝纤维化检测的动态变化,实现肝相关事件的个体化风险预测。模型区分度曲线下面积从基线88.2%升至5年随访92.2%,校准良好。
要点
- JLCM整合LSM轨迹、FIB-4和血小板等动态预测MASLD患者肝相关事件风险。
- 模型5年随访AUC达92.2%,优于单用LSM或FIB-4识别高风险患者。
- 动态预测可输出个体化0%-100%风险,辅助临床分层管理。
核心结论
- JLCM通过自动整合和解读无创肝纤维化检测的动态变化,实现MASLD患者肝相关事件的个体化预测。
研究设计与样本
- 研究使用国际多中心VCTE-Prognosis队列,纳入接受振动控制瞬时弹性成像肝硬度检测的成人MASLD患者13627例。
主要发现
- 中位随访4.0年(四分位距2.1-5.9年)期间发生238例肝相关事件。
- JLCM预测肝相关事件的整合AUC从基线88.2%升至5年随访92.2%。
- 各随访点JLCM识别61%-80%的肝相关事件患者为高风险,而LSM为39%-56%,FIB-4为32%-60%。
关键数值与推荐
- JLCM纵向部分纳入校正FIB-4和性别的LSM轨迹,生存部分纳入年龄和血小板。
- 校准图显示预测风险与观察风险高度一致。
临床怎么用
- 临床可利用JLCM动态整合无创检测结果,输出个体化肝相关事件风险,辅助风险分层和随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The evolution of noninvasive tests of liver fibrosis during follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) remains difficult to interpret in clinical practice. We aimed to translate the dynamics of noninvasive tests into a personalized prediction of liver-related events (LREs) in MASLD. METHODS: We used the international multicenter VCTE-Prognosis cohort including adult patients with MASLD who underwent liver stiffness measurements (LSMs) by vibration-controlled transient elastography. The study outcome was LRE, a composite endpoint including cirrhosis decompensation or hepatocellular carcinoma. A joint latent class model (JLCM) was used to compute dynamic predictions resulting in a personalized estimation of the risk of LREs (0%-100% at chosen time horizons). RESULTS: A total of 13,627 patients were included, with 238 LREs occurring during the median follow-up of 4.0 years (interquartile range, 2.1-5.9 years). LSM trajectory adjusted on the Fibrosis-4 Index and sex (longitudinal part) and age with platelets (survival part) were selected by the JLCM for LRE prediction. Calibration plots showed very good agreement between the predicted and the observed risk of LRE. The JLCM provided excellent discrimination for LRE with integrated areas under the receiver operating characteristic curve increasing from 88.2% at baseline to 92.2% at the 5-year follow-up visit. At the different study visits, 61%-80% of the patients who experienced LREs were identified as high risk by the JLCM, vs 39%-56% with LSM and 32%-60% with the Fibrosis-4 Index. CONCLUSIONS: By automatically integrating and interpreting the dynamics of noninvasive tests of liver fibrosis, JLCM enables the personalized prediction of the risk of hard outcomes, rather than the imperfect evaluation of histologic surrogates.
引用
- Moreau C, Roux M, Riou J, et al. Personalized Prediction of the Individual Risk of Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease Using the Dynamics of Noninvasive Tests. Clin Gastroenterol Hepatol. 2026. PMID: 42710771. doi:10.1016/j.cgh.2026.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。